Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 19/20 | 1.00 |
| ▸ | HRH1 | P35367 | 18/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.87 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18841162 | 1.00 | CCR3 (1.00) | CCR3HRH1KCNH2CCR5DRD2 | |
| SCHEMBL180058 | 0.93 | HRH1 (1.00) | CCR3HRH1KCNH2 | |
| SCHEMBL180012 | 0.93 | HRH1 (1.00) | CCR3HRH1KCNH2 | |
| SCHEMBL180011 | 0.93 | HRH1 (1.00) | CCR3HRH1KCNH2 | |
| SCHEMBL30397281 | 0.93 | HRH1 (1.00) | CCR3HRH1KCNH2 | |
| Water SCHEMBL180418 | 0.92 | HRH1 (0.98) | CCR3HRH1KCNH2 | |
| Water SCHEMBL27717183 | 0.92 | HRH1 (0.98) | CCR3HRH1KCNH2 | |
| Alcohol SCHEMBL180256 | 0.92 | HRH1 (0.97) | CCR3HRH1KCNH2 | |
| SCHEMBL180359 | 0.87 | HRH1 (0.86) | CCR3HRH1KCNH2 | |
| SCHEMBL180056 | 0.86 | HRH1 (1.00) | CCR3HRH1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10401365-B2 | Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer | UNIVERSITE PAUL SABATIER (TOULOUSE III) (FR) | 2019-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10401365-B2 | Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer | CCR3, CCR5, CCR1 | CCR3 1/4885HRH1 1870/4885KCNH2 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.